1. Introduction {#sec1-jcm-08-01431}
===============

Gestational diabetes mellitus (GDM) is defined as diabetes diagnosed in the second or third trimester of pregnancy provided that overt diabetes has been excluded in early pregnancy \[[@B1-jcm-08-01431]\]. Women with a history of GDM are at an increased risk of developing type 2 diabetes mellitus (T2DM) postpartum and also have a significantly higher risk of developing a metabolic syndrome and cardiovascular diseases compared to women with normal glucose tolerance (NGT) in pregnancy \[[@B2-jcm-08-01431],[@B3-jcm-08-01431]\]. The diagnostic criteria for GDM were initially based on the postpartum risk of developing T2DM, as proposed by the Carpenter and Coustan (CC) criteria, while the World Health Organization (WHO) initially defined GDM as impaired glucose tolerance (IGT) outside pregnancy \[[@B4-jcm-08-01431]\]. Based on the "Hyperglycemia and Adverse Pregnancy Outcome" (HAPO) study, a universal one-step diagnostic approach with a 75 g oral glucose tolerance test (OGTT) and more stringent diagnostic criteria for GDM were proposed in 2010 by the "International Association of Diabetes and Pregnancy Study Groups" (IADPSG) \[[@B5-jcm-08-01431],[@B6-jcm-08-01431]\]. The IADPSG criteria are the first diagnostic criteria for GDM based on adverse pregnancy outcomes and have now been endorsed by several national and international societies, including the WHO since 2013 \[[@B7-jcm-08-01431]\]. A systematic review of 2009, published before the introduction of the IADPSG criteria, showed that women with GDM have a seven-fold increased risk of developing T2DM later in life compared to NGT women during pregnancy \[[@B2-jcm-08-01431]\]. A subgroup analysis showed no difference in the postpartum risk for T2DM when women were stratified according to the different diagnostic criteria used for GDM \[[@B2-jcm-08-01431]\]. However, this systematic review included mostly old studies and was performed before the introduction of the IADPSG criteria for GDM. A systematic review from 2018 included more recent studies and confirmed the seven-fold increased postpartum risk for T2DM but did not evaluate the postpartum risk based on the IADPSG criteria compared to other criteria \[[@B8-jcm-08-01431]\]. The IADPSG screening strategy identifies women with milder degrees of hyperglycemia during pregnancy compared to other diagnostic criteria and screening strategies (two-step or selective screening), which might lead to a lower proportion at risk of postpartum glucose intolerance \[[@B9-jcm-08-01431],[@B10-jcm-08-01431],[@B11-jcm-08-01431]\]. Our objective was therefore to assess the postpartum risk for glucose intolerance and cardiovascular events in women with GDM based on the IADPSG criteria compared to other diagnostic criteria.

2. Methods {#sec2-jcm-08-01431}
==========

2.1. Protocol and Registration {#sec2dot1-jcm-08-01431}
------------------------------

Data were reported in accordance with the Guidelines for Meta-Analyses and Systematic Reviews of Observational Studies (MOOSE) \[[@B12-jcm-08-01431]\]. The study protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO) under the following identification number: CRD42018102315.

2.2. Data Sources and Searches {#sec2dot2-jcm-08-01431}
------------------------------

We searched MEDLINE, EMBASE, Web of Science, the Cochrane Library, and Latin American and Caribbean Health Sciences Literature (LILACS) up to 20 January 2019 for eligible studies published after 2009. Electronic searches were supplemented with manual searches of references of included studies. The journals Diabetes Care and Diabetologia (including special supplements) were screened for possible relevant articles. [Table S1](#app1-jcm-08-01431){ref-type="app"} shows our detailed search strategy. This was developed in consultation with biomedical reference librarians of the Catholic University of Leuven (KU Leuven).

2.3. Study Selection {#sec2dot3-jcm-08-01431}
--------------------

We included retrospective and prospective cohort, case-control and cross-sectional studies that evaluated the postpartum risk of glucose intolerance (T2DM and IGT (defined as impaired fasting glycemia and/or impaired glucose tolerance based on the 2 h glycemia on the OGTT)) or cardiovascular events (myocardial infarction or stroke) in women with a history of GDM. The study selection was performed by two investigators (K.B. and K.L.) independently. To be included, studies had to be published after 2009 (after the introduction of the IADPSG criteria), have a minimum follow-up period of six weeks after the index pregnancy, and contain a control group without a history of GDM. The control NGT group could be matched or not matched to the GDM group. No matched controls were defined as NGT women not matched by other characteristics (such as age and body mass index (BMI)) to the GDM group. Studies were included independent of which GDM screening strategy or diagnostic criteria were used. Studies including women with type 1 diabetes, T2DM, or with overt diabetes in early pregnancy were excluded. No language restriction was applied, but studies written in languages other than English, French, or Spanish were only included if they could be adequately translated using Google Translate.

2.4. Data Extraction {#sec2dot4-jcm-08-01431}
--------------------

Studies were uploaded in Endnote (version X9). Duplicated records were removed using Endnote software and by performing a manual search. Two investigators (K.B. and K.L.) independently reviewed and extracted relevant data from each included report using pre-designed forms. Any disagreement in data extraction was reconciled by consensus. If needed, a third reviewer (J.B.) was consulted. Extracted data included study setting, design, participant characteristics (country, origin, definition of control group, family history of T2DM, personal history of GDM, maternal age and body mass index (BMI, kg/m^2^) in the index pregnancy and at follow-up, and parity), characteristics about the diagnosis of GDM, IGT, and T2DM (timing of screening, screening strategy, diagnostic criteria), outcome data, and follow-up data (duration and loss to follow-up). The origin of women was considered to be mixed if \<80% of the study participants had the same ethnicity. When studies reported data concerning the risk for T2DM at multiple time points after the index pregnancy, the data with the longest follow-up were extracted since the risk for glucose intolerance increases with the duration of the follow-up. Authors were contacted for missing outcome data.

2.5. Outcomes {#sec2dot5-jcm-08-01431}
-------------

Outcomes included T2DM as the primary outcome and IGT, myocardial infarction, and stroke as the secondary outcomes. No restrictions were applied concerning the strategy (fasting glycemia, OGTT, or HbA1c) or diagnostic criteria used to define glucose intolerance postpartum.

2.6. Data Synthesis and Analysis {#sec2dot6-jcm-08-01431}
--------------------------------

Pooled analyses and subgroup analyses were conducted on Review Manager (RevMan), version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) using the DerSimonian and Laird random-effects model and Mantel--Haenszel methods, given their better statistical properties in case of sparse data, to calculate the summary relative risk (RR). Unadjusted absolute risks were determined. Heterogeneity was assessed using the Cochran Q statistic and quantified using the I^2^ statistic, where I^2^ \> 50% was considered as important heterogeneity \[[@B13-jcm-08-01431]\]. We investigated potential sources of heterogeneity by performing the following subgroup analyses for T2DM and IGT: duration of postpartum follow-up (\<3 years, ≥3 to \<6 years, ≥6 to \<10 years, ≥10 to \<15 years, ≥15 to \<20 years, ≥20 years, or not reported), maternal age during pregnancy and at follow-up (\<30 years, ≥30 to \<35 years, ≥35 years, or not reported), maternal BMI during pregnancy and at follow-up (\<25 kg/m^2^, ≥25 to \<30 kg/m^2^, ≥30 kg/m^2^, or not reported), origin (White, Asian, Pacific Islanders, Middle Eastern, mixed, or not reported), diagnostic criteria, and screening strategy used for GDM and glucose intolerance postpartum. Heterogeneity within and between subgroups was assessed using the I^2^-test, with a significance level of 0.10.

Sensitivity analyses were performed to evaluate whether the conclusions would have differed if eligibility had been restricted to studies with good quality according to the Newcastle--Ottawa Scale (NOS) or prospective cohort studies.

2.7. Quality Assessment {#sec2dot7-jcm-08-01431}
-----------------------

The same two reviewers (K.B. and K.L.) independently evaluated the quality of the studies in accordance with NOS \[[@B14-jcm-08-01431]\]. The quality assessment was divided into good quality (three or four stars for selection, one or two stars for comparability, and two or three stars for outcome/exposure), fair quality (two stars for selection, one or two stars for comparability, and two or three stars for outcome/exposure), and poor quality (none or one star for selection, no stars for comparability, or none or one star for outcome/exposure). In order to investigate possible publication bias, we performed a visual inspection of funnel plots.

3. Results {#sec3-jcm-08-01431}
==========

3.1. Search Results {#sec3dot1-jcm-08-01431}
-------------------

[Figure 1](#jcm-08-01431-f001){ref-type="fig"} shows the literature search and selection process. Our initial search yielded 7970 publications, of which 109 articles were reviewed in full and 43 studies were included in the final analysis \[[@B3-jcm-08-01431],[@B11-jcm-08-01431],[@B15-jcm-08-01431],[@B16-jcm-08-01431],[@B17-jcm-08-01431],[@B18-jcm-08-01431],[@B19-jcm-08-01431],[@B20-jcm-08-01431],[@B21-jcm-08-01431],[@B22-jcm-08-01431],[@B23-jcm-08-01431],[@B24-jcm-08-01431],[@B25-jcm-08-01431],[@B26-jcm-08-01431],[@B27-jcm-08-01431],[@B28-jcm-08-01431],[@B29-jcm-08-01431],[@B30-jcm-08-01431],[@B31-jcm-08-01431],[@B32-jcm-08-01431],[@B33-jcm-08-01431],[@B34-jcm-08-01431],[@B35-jcm-08-01431],[@B36-jcm-08-01431],[@B37-jcm-08-01431],[@B38-jcm-08-01431],[@B39-jcm-08-01431],[@B40-jcm-08-01431],[@B41-jcm-08-01431],[@B42-jcm-08-01431],[@B43-jcm-08-01431],[@B44-jcm-08-01431],[@B45-jcm-08-01431],[@B46-jcm-08-01431],[@B47-jcm-08-01431],[@B48-jcm-08-01431],[@B49-jcm-08-01431],[@B50-jcm-08-01431],[@B51-jcm-08-01431],[@B52-jcm-08-01431],[@B53-jcm-08-01431],[@B54-jcm-08-01431],[@B55-jcm-08-01431]\]. Forty studies reported on T2DM \[[@B3-jcm-08-01431],[@B11-jcm-08-01431],[@B15-jcm-08-01431],[@B16-jcm-08-01431],[@B17-jcm-08-01431],[@B18-jcm-08-01431],[@B19-jcm-08-01431],[@B20-jcm-08-01431],[@B21-jcm-08-01431],[@B22-jcm-08-01431],[@B23-jcm-08-01431],[@B24-jcm-08-01431],[@B25-jcm-08-01431],[@B26-jcm-08-01431],[@B27-jcm-08-01431],[@B28-jcm-08-01431],[@B29-jcm-08-01431],[@B30-jcm-08-01431],[@B31-jcm-08-01431],[@B32-jcm-08-01431],[@B33-jcm-08-01431],[@B34-jcm-08-01431],[@B35-jcm-08-01431],[@B36-jcm-08-01431],[@B37-jcm-08-01431],[@B38-jcm-08-01431],[@B39-jcm-08-01431],[@B40-jcm-08-01431],[@B41-jcm-08-01431],[@B42-jcm-08-01431],[@B43-jcm-08-01431],[@B44-jcm-08-01431],[@B45-jcm-08-01431],[@B46-jcm-08-01431],[@B47-jcm-08-01431],[@B48-jcm-08-01431],[@B49-jcm-08-01431],[@B50-jcm-08-01431],[@B51-jcm-08-01431],[@B55-jcm-08-01431]\], twenty-one on IGT \[[@B11-jcm-08-01431],[@B15-jcm-08-01431],[@B19-jcm-08-01431],[@B20-jcm-08-01431],[@B21-jcm-08-01431],[@B22-jcm-08-01431],[@B23-jcm-08-01431],[@B24-jcm-08-01431],[@B25-jcm-08-01431],[@B26-jcm-08-01431],[@B27-jcm-08-01431],[@B28-jcm-08-01431],[@B29-jcm-08-01431],[@B30-jcm-08-01431],[@B31-jcm-08-01431],[@B32-jcm-08-01431],[@B33-jcm-08-01431],[@B34-jcm-08-01431],[@B39-jcm-08-01431],[@B53-jcm-08-01431],[@B55-jcm-08-01431]\], and five studies on cardiovascular events \[[@B16-jcm-08-01431],[@B17-jcm-08-01431],[@B18-jcm-08-01431],[@B52-jcm-08-01431],[@B54-jcm-08-01431]\].

3.2. Study Characteristics {#sec3dot2-jcm-08-01431}
--------------------------

[Table 1](#jcm-08-01431-t001){ref-type="table"} shows the characteristics of included studies. Across all studies, the total number of pregnant women included was 4,923,571, of which 284,312 had GDM (5.8%). Of all studies, 18 (41.9%) included less than 200 women with GDM. The follow-up ranged from 12 weeks to 25.7 years postpartum, with a mean follow-up of 7.9 years. Of all included studies, 19 (44.2%) were prospective cohorts, 13 (30.2%) retrospective cohorts, 6 (14.0%) case-control studies, and 5 (11.6%) cross-sectional studies. Fifteen studies (34.9%) were performed in Europe, ten (23.3%) in Asia, fourteen (32.6%) in North America, three (7.0%) in Australia, and one (2.3%) was an international study. The mean maternal age at follow-up was 36.5 years with a median BMI at follow-up of 26.9 kg/m^2^. The drop-out rate was only reported in six (14.0%) studies---three had a non important (\<5%) drop-out and three studies reported a drop-out of \>20%.

The diagnostic criteria for GDM were reported in 29 (67.4%) studies, of which six (14.0%) used the 1999 WHO criteria, five (11.6%) the IADPSG criteria, six (14.0%) the CC criteria, four (9.3%) the Canadian Diabetes Association (CDA) criteria, two (4.7%) the Australasian Diabetes in Pregnancy Society (ADIPS) criteria, two (4.7%) the National Diabetes Data Group (NDDG) criteria, one (2.3%) the German Diabetes Association criteria, and three (7.0%) used other local criteria. The five studies using the IADPSG screening strategy, included 6174 women of which 1314 had GDM, with a mean follow-up of 5.6 years, mean maternal age at follow-up of 36.9 years, and median maternal BMI at follow-up of 29.3 kg/m^2^. Three studies were performed in Europe, one in Asia, and one was an international study.

The screening strategy for GDM was reported in 24 (55.8%) studies, of which three (7.0%) used screening for GDM based on risk factors, 10 (23.3%) studies used a two-step screening strategy with a glucose challenge test (GCT), and 11 (25.6%) studies used a universal one-step approach with a 75 g OGTT. T2DM was defined according to the ADA criteria in 13 (32.5%) studies, the WHO criteria in seven (17.5%) studies, the CDA criteria in three (7.5%) studies, and the German Diabetes Association criteria in one study (2.5%). IGT was defined according to the ADA criteria in nine (42.9%) studies, the WHO criteria in five (23.8%) studies, and the CDA criteria in three (14.3%) studies.

3.3. Postpartum Risk of Type 2 Diabetes {#sec3dot3-jcm-08-01431}
---------------------------------------

[Figure 2](#jcm-08-01431-f002){ref-type="fig"}A shows the overall postpartum risk for T2DM in women with a history of GDM compared to NGT women. The risk for T2DM stratified according to the IADPSG criteria compared to other diagnostic criteria is reported in [Table 2](#jcm-08-01431-t002){ref-type="table"}A. The overall pooled RR for postpartum T2DM was 7.42 (95% CI: 5.99--9.19). The RR for postpartum T2DM for GDM based on the IADPSG criteria was 6.45 (95% CI: 4.74--8.77) compared to a RR of 9.08 (95% CI: 6.96--11.85; *p* = 0.17) for GDM based on other diagnostic criteria. There was substantial heterogeneity across different subgroups ([Table 2](#jcm-08-01431-t002){ref-type="table"}A). The highest RR for T2DM was seen within the first 6 years after the index pregnancy. The risk for T2DM decreased with a longer follow-up period but remained significantly increased in comparison to NGT women. The RR was highest in women aged ≥30 to \<35 years at follow-up, among women with a BMI ≥ 30 kg/m^2^ during pregnancy, in women with a BMI \< 25 kg/m^2^ at follow-up, and in women with a White or mixed origin. The RR for postpartum T2DM was not significantly different according to the screening strategy used for GDM or the screening strategy used for T2DM postpartum.

3.4. Postpartum Risk of Impaired Glucose Tolerance {#sec3dot4-jcm-08-01431}
--------------------------------------------------

[Figure 2](#jcm-08-01431-f002){ref-type="fig"}B shows the overall postpartum risk for IGT in women with a history of GDM compared to NGT women. The risk for IGT stratified according to studies using the IADPSG criteria compared to other criteria is reported in [Table 2](#jcm-08-01431-t002){ref-type="table"}B. The overall pooled RR for postpartum IGT was 2.45 (95% CI: 1.92--3.13). The RR for postpartum IGT for GDM based on the IADPSG criteria was 2.79 (95% CI: 1.30--5.96) compared to a RR of 2.03 (95% CI: 1.57--2.62; *p* = 0.73) for GDM based on other diagnostic criteria. Heterogeneity was substantial across different subgroups ([Table 2](#jcm-08-01431-t002){ref-type="table"}B). The highest RR for IGT was seen within the first 3 years after the index pregnancy. The risk for IGT decreased with a longer follow-up period but remained significantly increased in comparison to NGT women. The RR was highest in women with a BMI ≥30 kg/m^2^ during pregnancy, in women with a BMI of 25--30 kg/m^2^ at follow-up, and in women with a White or mixed origin. The RR for IGT was not significantly different according to the screening strategy used for GDM or according to the diagnostic criteria used for IGT or maternal age during pregnancy or postpartum.

3.5. Sensitivity Analyses {#sec3dot5-jcm-08-01431}
-------------------------

Studies with good quality according to the NOS showed a much higher RR for T2DM of 15.21 (95% CI 8.36--27.69), while prospective cohort studies showed a lower RR for T2DM of 4.41 (95% CI: 3.64--5.35) compared to the overall effect ([Table S3](#app1-jcm-08-01431){ref-type="app"}). Studies with good quality according to the NOS showed a higher RR for IGT of 4.57 (95% CI: 2.13--9.80), while prospective cohort studies showed a similar RR for IGT of 2.41 (95% CI: 1.87--3.10) as the overall effect ([Table S2](#app1-jcm-08-01431){ref-type="app"}).

3.6. Postpartum Risk of Cardiovascular Events {#sec3dot6-jcm-08-01431}
---------------------------------------------

[Figure 2](#jcm-08-01431-f002){ref-type="fig"}C shows the overall postpartum risk for stroke and myocardial infarction in women with a history of GDM compared to NGT women. RR for stroke was 1.23 (95% CI: 1.09--1.38) and RR for myocardial infarction was 1.85 (95% CI: 1.53--2.24). Of all studies evaluating cardiovascular events, none used the IADPSG criteria. Three studies reported on the postpartum risk of both T2DM and cardiovascular events \[[@B16-jcm-08-01431],[@B17-jcm-08-01431],[@B18-jcm-08-01431]\]. However, only one study reported on the cardiovascular risk in women with previous GDM with and without T2DM and showed that women with GDM without T2DM had no increased risk (RR for stroke of 0.94 (95% CI: 0.63--1.41) and RR for myocardial infarction of 1.26 (95% CI: 0.90--1.76)), while women with GDM and T2DM had a significantly increased risk for myocardial infarction (RR of 1.28 (95% CI: 0.64--2.58) for stroke and RR for myocardial infarction of 1.93 (95% CI: 1.12--3.33)) \[[@B17-jcm-08-01431]\].

3.7. Publication Bias {#sec3dot7-jcm-08-01431}
---------------------

The funnel plots are shown in [Figure S1](#app1-jcm-08-01431){ref-type="app"}. Since the estimated RRs for individual studies had a similar value, a visual inspection of the funnel plots for T2DM and cardiovascular events was not applicable. A visual inspection of the funnel plot for IGT suggested the absence of publication bias or only a small effect.

3.8. Assessment of Quality {#sec3dot8-jcm-08-01431}
--------------------------

[Table S3](#app1-jcm-08-01431){ref-type="app"} shows the quality of studies according to the NOS. Of all the 40 studies for T2DM, 30 (75.0%) had poor quality. The poor quality was mostly due to the absence of a matched control group. Of all the studies for IGT and cardiovascular events, 15 (71.4%) and 3 (60.0%), respectively, had poor quality.

4. Discussion {#sec4-jcm-08-01431}
=============

4.1. Summary of Findings {#sec4dot1-jcm-08-01431}
------------------------

The present systematic review and meta-analysis of 43 studies, including nearly five million pregnant women of which 6% (about 280,000) had prior GDM, showed that women with a history of GDM based on the IADPSG criteria have a similarly increased risk for postpartum glucose intolerance compared to GDM based on other diagnostic criteria and other GDM screening strategies. Overall, women with GDM have a seven-fold increased risk of developing T2DM, a two-fold increased risk of developing IGT, and about a 1.5 times increased risk for cardiovascular events later in life compared to NGT women during pregnancy. This might be an underestimation, as the sensitivity analyses showed that the highest quality studies demonstrated a fifteen-fold increased risk for T2DM and a four-fold increased risk for IGT in women with a history of GDM compared to NGT women. The highest risk for developing glucose intolerance was present within the 3--6 years after the index pregnancy. In addition, the highest risk for T2DM was present in White and mixed-race women, in women with higher age and higher BMI during pregnancy, and in normal weight women at follow-up. The highest risk for IGT was present in obese women during pregnancy and in White and mixed-race women.

4.2. Results in Relation to What We Already Know {#sec4dot2-jcm-08-01431}
------------------------------------------------

Our findings extend those of previous systematic reviews and meta-analyses showing that women with GDM have a seven-fold increased risk of developing T2DM later in life compared to NGT women during pregnancy \[[@B2-jcm-08-01431],[@B8-jcm-08-01431]\]. The first systematic review of 2009 included twenty cohort studies and showed no significant heterogeneity from the subgroup analysis of the criteria used for the diagnosis of GDM and T2DM \[[@B2-jcm-08-01431]\]. However, this systematic review included older studies and was performed before the introduction of the IADPSG criteria for GDM. In contrast to our systematic review, effect estimates were broadly consistent in all subgroups analyzed (such as ethnic origin, follow-up time, maternal age, and BMI) \[[@B2-jcm-08-01431]\]. The most recent systematic review and meta-analysis from 2018 evaluated more than 2 million pregnant women from thirty cohort studies and confirmed the unadjusted seven-fold increased postpartum risk for T2DM. However, this review did not evaluate the postpartum risk based on the IADPSG criteria compared to other diagnostic criteria for GDM \[[@B8-jcm-08-01431]\]. Twenty-eight cohorts reported the diagnostic criteria used for GDM but none of the included studies used the IADPSG criteria for GDM. In line with the results of our systematic review, the 2018 review showed that the highest risk for T2DM was present within 3--6 years after the index pregnancy and that women with normal weight at follow-up had the highest RR for T2DM \[[@B8-jcm-08-01431]\]. As in our systematic review, women with a White origin had a higher RR of postpartum T2DM than Asian women. As in previous systematic reviews, no significant heterogeneity was observed according to the screening strategy used for GDM or according to the screening strategy and diagnostic criteria used for glucose intolerance postpartum \[[@B2-jcm-08-01431],[@B8-jcm-08-01431]\].

To date, long-term data on the risk of T2DM developing in women with GDM diagnosed by the universal IADPSG screening strategy have been limited. In general, the IADPSG screening strategy identifies women with milder degrees of hyperglycemia during pregnancy compared to other diagnostic criteria and screening strategies (two-step or selective screening), which might lead to a lower proportion at risk of postpartum glucose intolerance \[[@B9-jcm-08-01431],[@B10-jcm-08-01431],[@B11-jcm-08-01431]\]. We have previously shown glucose intolerance in 42% of women three months after a pregnancy with GDM diagnosed by a two-step screening strategy with a GCT, while less than 20% of women had glucose intolerance in early postpartum after a GDM pregnancy based on a universal one-step diagnostic approach with the IADPSG criteria \[[@B9-jcm-08-01431],[@B10-jcm-08-01431]\]. A follow-up of the HAPO study 10--14 years postpartum showed that untreated women with GDM, defined post hoc by the IADPSG criteria, had significantly higher rates of a glucose metabolism disorder than women without GDM (52.2% vs. 20.1% (T2DM 10.7% vs. 1.6%)) \[[@B11-jcm-08-01431]\]. However, GDM, according to the CC criteria, was associated with a much higher risk for T2DM (20% vs. 7.9%) compared to women with GDM according to the IADPSG criteria alone \[[@B11-jcm-08-01431]\]. Our systematic review includes the largest number of studies to date on the risk for T2DM after GDM and presents the first summarized data on the risk for glucose intolerance postpartum in GDM based on the IADPSG criteria compared to GDM based on other diagnostic criteria. In addition, we have shown that women with previous GDM are also at increased risk of stroke and myocardial infarction. This is in line with a recent meta-analysis showing that women with GDM had a two-fold higher risk for future cardiovascular events and that this cardiovascular risk is independent of the intercurrent development of T2DM \[[@B56-jcm-08-01431]\].

4.3. Implications {#sec4dot3-jcm-08-01431}
-----------------

Our study has important public health implications. The IADPSG criteria are the first diagnostic criteria based on pregnancy outcomes. By implementing the IADPSG screening strategy, important adverse pregnancy outcomes can be prevented. However, due to concerns concerning the increased workload and associated costs, the adoption of the IADPSG screening strategy varies worldwide \[[@B57-jcm-08-01431]\]. The limited data on the long-term risk for glucose intolerance postpartum in women with GDM based on the IADPSG criteria contribute to the ongoing discussion on whether implementing the IADPSG screening strategy will be cost-effective. Our data show that women with GDM based on the IADPSG criteria have a similarly increased risk for glucose intolerance postpartum compared to women with GDM based on other diagnostic criteria or other screening strategies for GDM. Since the implementation of the IADPSG screening strategy has led to an important increase in the prevalence of GDM, this might offer a window of opportunity to identify a large group of women at increased risk of glucose intolerance later in life. This can help to timely implement strategies to prevent the development of T2DM. Our data confirm that the highest RR to develop glucose intolerance is present within the first three to six years after the index pregnancy, highlighting the importance to start early after delivery with screening and prevention programs in this high-risk group to prevent and timely detect T2DM. In addition, continued follow-up beyond six years postpartum remains important since the risk to develop glucose intolerance over time remains significantly higher compared to women without a history of GDM. Our data also show that women with a White origin and women with normal weight at follow-up have the highest risks to develop T2DM. This might suggest that GDM identifies a high-risk group for T2DM at a young age due to beta-cell dysfunction and that genetic predisposition might play an important role in Caucasian women. However, caution for interpretation is warranted since many subgroup analyses were based on a limited number of studies and the majority of studies evaluated Caucasian women.

4.4. Strengths and Limitations {#sec4dot4-jcm-08-01431}
------------------------------

This systematic review and meta-analysis included the largest number of studies to date on the long-term risk for glucose intolerance after GDM. In contrast to other systematic reviews, our review included only recent studies published after 2009, and we did not only include cohort studies but also case-control and cross-sectional studies provided they met the eligible criteria \[[@B2-jcm-08-01431],[@B8-jcm-08-01431]\]. In addition, our study provides the first data on the long-term risk for glucose intolerance in women with GDM based on the IADPSG criteria. However, our study has several limitations. Due to the language barrier, we only searched studies published in English, French, and Spanish. However, we only had to exclude one study due to the language used (Chinese). Several key variables, such as BMI and data on the family history of GDM and family history of T2DM, were absent in many studies. We contacted the authors to limit the number of missing variables. The overall quality of the studies was low, often due to the lack of a matched control group. In addition, nearly one-third of the studies did not report the diagnostic criteria used for GDM. Moreover, since the IADPSG criteria have only been recommended since 2010, only five studies with GDM based on the IADPSG criteria were identified and none of the studies evaluating the risk for cardiovascular events used the IADPSG criteria. More studies with GDM based on the IADPSG criteria and with a longer follow-up are needed to increase the quality of evidence concerning the long-term metabolic risk.

5. Conclusions {#sec5-jcm-08-01431}
==============

Women with a history of GDM based on the IADPSG criteria have a similarly increased risk for postpartum glucose intolerance compared to GDM based on other diagnostic criteria and other screening strategies. Women with GDM have a seven-fold increased risk of developing T2DM, a two-fold increased risk of developing IGT, and about a 1.5 times increased risk for cardiovascular events later in life compared to NGT women during pregnancy. As the relative increase in risk for T2DM is highest within the first six years after delivery, screening and prevention strategies should be implemented within the first years after the index pregnancy.
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The overall postpartum risk for glucose intolerance and cardiovascular events in women with a history of GDM compared to NGT women: (**A**) Type 2 diabetes mellitus (T2DM), (**B**) prediabetes, (**C1**) stroke, and (**C2**) myocardial infarction. T2DM: Type 2 diabetes mellitus; GDM, gestational diabetes mellitus; 95% CI: confidence interval; M--H: Mantel--Haenszel method; df: degrees of freedom; RR: relative risk or risk ratio. X-axis is log scale of RR. Squares represent the RR of an individual study. The size of the square is proportional to the weight of the study, which was calculated using a random-effects model. The horizontal lines indicate 95% CI. The diamond represents the pooled RR with its 95% CI.
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###### 

The characteristics of included studies: (**A**) study and patient characteristics, (**B**) characteristics concerning GDM, T2DM, and prediabetes, and (**C**) characteristics concerning stroke and myocardial infarction.

  ------------------------------------------------------ ---------------------------------------------- -------------------------- --------------------------- ------------------------------------------ ------------------------------------------------------------------------------------------------------------ ------------------------------ ------------------------------------------------- ----------------------------
  **A.**                                                                                                                                                                                                                                                                                                                                                                                                

                                                         **Study Type, Country**                        **Ethnic Origin**          **Age at Pregnancy, yr**\   **BMI at Pregnancy, kg/m^2^**\             **Definition NGT Group**                                                                                     **Duration of Follow-Up**\                                                       
                                                                                                                                   **Age at Follow-Up, yr**\   **BMI at Follow-Up, kg/m^2^**\                                                                                                                          **(± SD or IQR)**                                                                
                                                                                                                                   **(± SD or IQR)**           **(± SD or IQR)**                                                                                                                                                                                                                        

  Chodick et al. 2010 \[[@B37-jcm-08-01431]\]            Retrospective cohort study, Israel             NR                         NR\                         NR\                                        No matched controls                                                                                          5.7 (± 4.0)                                                                      
                                                                                                                                   32.7 ± 5.5                  63.2% \< 25                                                                                                                                                                                                                              

  Pirkola et al. 2010 \[[@B38-jcm-08-01431]\]            Prospective cohort study, Finland              NR                         NR\                         NR\                                        No matched controls                                                                                          20.0                                                                             
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Akinci et al. 2011 \[[@B21-jcm-08-01431]\]             Case-control study, Turkey                     Caucasian                  NR\                         NR\                                        Controls (hospital staff) matched for age, and time period of pregnancy                                      3.4 (± 1.9)                                                                      
                                                                                                                                   31.9 ± 5.3                  27.1 ± 5.4                                                                                                                                                                                                                               

  Anderberg et al. 2011 \[[@B22-jcm-08-01431]\]          Prospective cohort study, Sweden               Mixed                      33.1 ± 4.9\                 NR\                                        Controls matched by random sampling for residency                                                            1.3 (1.1--1.6)                                                                   
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Freibert et al. 2011 \[[@B54-jcm-08-01431]\]           Cross-sectional study, USA (Kentucky)          NR                         NR\                         NR\                                        No matched controls, women ≥ 50 years                                                                        NR                                                                               
                                                                                                                                   57.1 ± 5.5                  NR                                                                                                                                                                                                                                       

  O'Reilly et al. 2011 \[[@B23-jcm-08-01431]\]           Prospective cohort study, Ireland              Caucasian                  NR\                         NR\                                        Controls matched for residency, and time period of pregnancy                                                 0.23                                                                             
                                                                                                                                   33.5 ± 4.7                  NR                                                                                                                                                                                                                                       

  Xiang et al. 2011 \[[@B39-jcm-08-01431]\]              Retrospective cohort study, USA (California)   Mixed                      NR\                         NR\                                        Five matched controls for each GDM by random sampling for ethnicity, age, and calendar year of study entry   3.9--5.2 (IQR NR)                                                                
                                                                                                                                   32.4 ± 5.2                  NR                                                                                                                                                                                                                                       

  Anderberg et al. 2012 \[[@B40-jcm-08-01431]\]          Case-control study, Sweden                     NR                         NR\                         NR\                                        Two matched controls for each GDM for year of birth, year of delivery, and municipality of residence         8.0--14.0                                                                        
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Sokup et al. 2012 \[[@B55-jcm-08-01431]\]              Cross-sectional study, Poland                  Caucasian                  NR\                         NR\                                        No matched controls                                                                                          0.17--2                                                                          
                                                                                                                                   29.0 (26.0--35.0)           23.7 (21.0--27.5)                                                                                                                                                                                                                        

  Tehrani et al. 2012 \[[@B41-jcm-08-01431]\]            Case-control study, Iran                       Middle-Eastern             NR\                         NR\                                        Matched controls for age, and BMI from the TLGS cohort                                                       9.0                                                                              
                                                                                                                                   33.6 ± 7.5                  30.0 ± 4.7                                                                                                                                                                                                                               

  Wang et al. 2012 \[[@B42-jcm-08-01431]\]               Prospective cohort study, USA (Louisiana)      Mixed                      NR\                         NR\                                        Controls matched for age, and time period of pregnancy                                                       8.6 (± NR)                                                                       
                                                                                                                                   26.8 ± 0.2                  48.2 ± 1.7                                                                                                                                                                                                                               

  Barden et al. 2013 \[[@B43-jcm-08-01431]\]             Case-control study, Australia                  Mixed                      31.3 ± 0.4 (high risk),\    35.5 ± 5.0 (high risk),\                   No matched controls                                                                                          10.0                                                                             
                                                                                                                                   33.8 ± 0.5 (low risk)\      27.3 ± 4.1 (low risk)\                                                                                                                                                                                                                   
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Hummel et al. 2013 \[[@B24-jcm-08-01431]\]             Prospective cohort study, Germany              NR                         NR                          NR\                                        No matched controls                                                                                          5.5 (IQR NR)                                                                     
                                                                                                                                                               NR                                                                                                                                                                                                                                       

  Moleda et al. 2013 \[[@B25-jcm-08-01431]\]             Prospective cohort study, Poland               Caucasian                  30.8 ± 5.7\                 22.4 ± 3.4\                                Controls matched for age, and time period of delivery                                                        7.4 (± 0.7)                                                                      
                                                                                                                                   NR                          25.5 ± 5.6                                                                                                                                                                                                                               

  Huopio et al. 2014 \[[@B17-jcm-08-01431]\]             Prospective cohort study, Finland              Caucasian                  32.0 ± 5.9\                 26.4 ± 4.8\                                No matched controls                                                                                          7.3 (± 5.1)                                                                      
                                                                                                                                   NR                          28.4 ± 5.5                                                                                                                                                                                                                               

  McKenzie-Sampson et al. 2018 \[[@B56-jcm-08-01431]\]   Retrospective cohort study, Canada             NR                         NR\                         NR\                                        No matched controls                                                                                          NR                                                                               
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Kramer et al. 2014 \[[@B57-jcm-08-01431]\]             Prospective cohort study, Canada               Mixed                      35 (33--38)\                NR\                                        No matched controls                                                                                          2.98 (± NR)                                                                      
                                                                                                                                   NR                          25.4 (22.4--30.1)                                                                                                                                                                                                                        

  Mai et al. 2014 \[[@B44-jcm-08-01431]\]                Case-control study, China                      NR                         NR\                         NR\                                        No matched controls                                                                                          2.5 (± 1.8)                                                                      
                                                                                                                                   33.1 ± 4.8                  22.7 ± 3.5                                                                                                                                                                                                                               

  Ajala et al. 2015 \[[@B26-jcm-08-01431]\]              Retrospective cohort study, Canada             Caucasian                  NR\                         NR\                                        No matched controls                                                                                          7.1 (± 1.6)                                                                      
                                                                                                                                   39.2 ± 4.1                  28.9 ± 6.6                                                                                                                                                                                                                               

  Cormier et al. 2015 \[[@B27-jcm-08-01431]\]            Prospective cohort study, Canada               Caucasian                  NR\                         NR\                                        No matched controls                                                                                          3.5 (± 2.0)                                                                      
                                                                                                                                   36.4 ± 4.9                  27.7 ± 6.5                                                                                                                                                                                                                               

  Kaul et al. 2015 \[[@B45-jcm-08-01431]\]               Retrospective cohort study, Canada             NR                         NR\                         NR\                                        No matched controls                                                                                          5.3 (2.2--8.4)                                                                   
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Lekva et al. 2015 \[[@B28-jcm-08-01431]\]              Prospective cohort study, Norway               Caucasian                  33.4 ± 4.54\                28.1 (26.7--30.1)\                         No matched controls                                                                                          5.0                                                                              
                                                                                                                                   NR                          22.6 (22.4--27.9)                                                                                                                                                                                                                        

  Pintaudi et al. 2015 \[[@B46-jcm-08-01431]\]           Retrospective cohort study, Italy              NR                         NR\                         NR\                                        Three matched controls for each GDM for propensity scores                                                    5.4 (2.9--7.3)                                                                   
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Sreelakshmi et al. 2015 \[[@B47-jcm-08-01431]\]        Retrospective cohort study, India              Asian                      NR\                         NR\                                        No matched controls                                                                                          4.0                                                                              
                                                                                                                                   NR                          24.6 ± 3.9                                                                                                                                                                                                                               

  Vigneault et al. 2015 \[[@B29-jcm-08-01431]\]          Cross-sectional study, Canada                  Caucasian                  NR\                         NR\                                        No matched controls                                                                                          3.9 (± NR)                                                                       
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Cho et al. 2016 \[[@B48-jcm-08-01431]\]                Retrospective cohort study, South Korea        NR                         NR\                         NR\                                        No matched controls                                                                                          8.0                                                                              
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Domínguez-Vigo et al. 2016 \[[@B49-jcm-08-01431]\]     Case-control study, Spain                      NR                         33.8 ± 4.9\                 NR\                                        No matched controls                                                                                          12.9 (± 0.4)                                                                     
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Goueslard et al. 2016 \[[@B20-jcm-08-01431]\]          Retrospective cohort study, France             NR                         NR\                         NR\                                        No matched controls                                                                                          7.0                                                                              
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Noctor et al. 2016 \[[@B30-jcm-08-01431]\]             Prospective cohort study, Ireland              Caucasian                  34.0 ± 5.0\                 31.3 ± 6.6\                                No matched controls                                                                                          2.6 (± NR)                                                                       
                                                                                                                                   NR                          29.7 ± 6.9                                                                                                                                                                                                                               

  Sina et al. 2016 \[[@B50-jcm-08-01431]\]               Prospective cohort study, Australia            Pacific Islanders          27.0 ± 6.7\                 NR\                                        No matched controls                                                                                          11.9 (7.3--17.0)                                                                 
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Bond et al. 2017 \[[@B51-jcm-08-01431]\]               Retrospective cohort study, Canada             Mixed                      NR\                         NR\                                        Controls matched for age, birth year, and residency                                                          12.5 (± 5.6)                                                                     
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Gadgil et al. 2017 \[[@B31-jcm-08-01431]\]             Cross-sectional study, USA                     Asian                      NR\                         NR\                                        No matched controls, no self-reported GDM                                                                    NR                                                                               
                                                                                                                                   51.1 ± 7.0                  26.7 ± 3.8                                                                                                                                                                                                                               

  Herath et al. 2017 \[[@B52-jcm-08-01431]\]             Retrospective cohort study, Sri Lanka          Asian                      31.7 ± 5.4\                 NR\                                        No matched controls, no self-reported GDM                                                                    10.9 (± 0.35)                                                                    
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Minooee et al. 2017 \[[@B32-jcm-08-01431]\]            Prospective cohort study, Iran                 NR                         NR\                         NR\                                        No matched controls                                                                                          12.1 (8.1--13.5)                                                                 
                                                                                                                                   36.5 ± 8.0                  28.4 ± 4.5                                                                                                                                                                                                                               

  Retnakaran et al. 2017 \[[@B3-jcm-08-01431]\]          Retrospective cohort study, Canada             NR                         NR\                         NR\                                        No matched controls                                                                                          10.0 (IQR NR)                                                                    
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Simmons et al. 2017 \[[@B33-jcm-08-01431]\]            Cross-sectional study, New Zealand             Pacific Islanders          NR\                         NR\                                        No matched controls, no self-reported GDM                                                                    NR                                                                               
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Tobias et al. 2017 \[[@B19-jcm-08-01431]\]             Prospective cohort study, USA                  Caucasian                  27.5 ± 4.8\                 21.5 ± 3.6\                                No matched controls, no self-reported GDM                                                                    25.7 (± NR)                                                                      
                                                                                                                                   NR                          25.8 ± 5.9                                                                                                                                                                                                                               

  Daly et al. 2018 \[[@B18-jcm-08-01431]\]               Retrospective cohort study, UK                 NR                         NR\                         NR\                                        Four matched controls for each GDM for age, and timing of pregnancy                                          2.9 (IQR NR)                                                                     
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Gunderson et al. 2018 \[[@B53-jcm-08-01431]\]          Prospective cohort study, USA                  NR                         NR\                         NR\                                        No matched controls, no self-reported GDM                                                                    24.7 (± 6.6)                                                                     
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Huvinen et al. 2018 \[[@B34-jcm-08-01431]\]            Prospective cohort study, Finland              NR                         NR\                         NR\                                        No matched controls                                                                                          5.0 (4.0--6.0)                                                                   
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  Lowe et al. 2018 \[[@B11-jcm-08-01431]\]               Prospective cohort study, International        Mixed                      NR\                         29.7 ± 5.2\                                No matched controls                                                                                          11.4 (10.6--2.2)                                                                 
                                                                                                                                   43.6 ± 5.4                  28.9 ± 6.5                                                                                                                                                                                                                               

  Shen et al. 2018 \[[@B35-jcm-08-01431]\]               Prospective cohort study, China                NR                         NR\                         NR\                                        No matched controls                                                                                          3.5 (± NR)                                                                       
                                                                                                                                   30.1 ± 3.5                  24.2 ± 3.9                                                                                                                                                                                                                               

  Sudasinghe et al. 2018 \[[@B36-jcm-08-01431]\]         Prospective cohort study, Sri Lanka            Asian                      NR\                         NR\                                        No matched controls                                                                                          1.0                                                                              
                                                                                                                                   NR                          NR                                                                                                                                                                                                                                       

  **B.**                                                                                                                                                                                                                                                                                                                                                                                                

                                                         **Screening Strategy for GDM**                 **Criteria for GDM**       **Criteria for T2DM**       **Postpartum Screening Method for T2DM**   **GDM T2DM/Total**\                                                                                          **Criteria for Prediabetes**   **Postpartum Screening Method for Prediabetes**   **GDM Prediabetes/Total**\
                                                                                                                                                                                                          **NGT T2DM/Total**\                                                                                                                                                                           **NGT Prediabetes/Total**\
                                                                                                                                                                                                          **(AR, %)**                                                                                                                                                                                   **(AR, %)**

  Chodick et al. 2010 \[[@B37-jcm-08-01431]\]            Universal two-step screening                   CC                         NR                          NR                                         1769/11,270 (15.7)\                                                                                          \-                             \-                                                \-
                                                                                                                                                                                                          1741/174,146 (1.0)                                                                                                                                                                            

  Pirkola et al. 2010 \[[@B38-jcm-08-01431]\]            Selective screening based on risk factors      NR                         NR                          NR                                         15/104 (14.4)\                                                                                               \-                             \-                                                \-
                                                                                                                                                                                                          29/981 (3.0)                                                                                                                                                                                  

  Akinci et al. 2011 \[[@B21-jcm-08-01431]\]             Universal two-step screening                   CC                         ADA                         OGTT                                       27/195 (13.8)\                                                                                               ADA                            OGTT                                              101/195 (51.8)\
                                                                                                                                                                                                          0/71 (0.0)                                                                                                                                                                                    2/71 (2.8)

  Anderberg et al. 2011 \[[@B22-jcm-08-01431]\]          NR                                             Local (Swedish) \*         WHO                         OGTT                                                                                                                                                    WHO                            OGTT                                              

  Freibert et al. 2011 \[[@B54-jcm-08-01431]\]           NR                                             NR                         \-                          \-                                         \-                                                                                                           \-                             \-                                                \-

  O'Reilly et al. 2011 \[[@B23-jcm-08-01431]\]           Universal one-step screening                   IADPSG                     ADA                         OGTT                                       9/300 (3.0)\                                                                                                 ADA                            OGTT                                              48/300 (16.0)\
                                                                                                                                                                                                          0/220 (0.0)                                                                                                                                                                                   6/220 (2.7)

  Xiang et al. 2011 \[[@B39-jcm-08-01431]\]              NR                                             CC                         ADA                         OGTT or HbA1c                              1539/12,998 (11.8)\                                                                                          \-                             \-                                                \-
                                                                                                                                                                                                          1118/64,668 (1.7)                                                                                                                                                                             

  Anderberg et al. 2012 \[[@B40-jcm-08-01431]\]          NR                                             NR                         NR                          NR                                         180/579 (31.1)\                                                                                              \-                             \-                                                \-
                                                                                                                                                                                                          13/1131 (1.1)                                                                                                                                                                                 

  Sokup et al. 2012 \[[@B55-jcm-08-01431]\]              Universal two-step screening                   WHO, 1999                  \-                          \-                                         \-                                                                                                           WHO                            OGTT                                              28/85 (32.9)\
                                                                                                                                                                                                                                                                                                                                                                                                        0/40 (0.0)

  Tehrani et al. 2012 \[[@B41-jcm-08-01431]\]            Universal one-step screening                   IADPSG                     ADA                         OGTT                                       8/29 (27.6)\                                                                                                 ADA                            OGTT                                              4/29 (13.8)\
                                                                                                                                                                                                          5/58 (8.6)                                                                                                                                                                                    9/58 (15.5)

  Wang et al. 2012 \[[@B42-jcm-08-01431]\]               NR                                             WHO, 1999                  WHO                         OGTT or FPG                                327/1142 (28.6)\                                                                                             \-                             \-                                                \-
                                                                                                                                                                                                          1067/18,856 (5.7)                                                                                                                                                                             

  Barden et al. 2013 \[[@B43-jcm-08-01431]\]             Universal one-step screening                   ADIPS                      NR                          FPG                                        20/112 (17.9)\                                                                                               \-                             \-                                                \-
                                                                                                                                                                                                          0/48 (0.0)                                                                                                                                                                                    

  Hummel et al. 2013 \[[@B24-jcm-08-01431]\]             Selective screening based on risk factors      GDA                        GDA                         OGTT, FPG or HbA1c                         8/102 (7.8)\                                                                                                 NR                             OGTT                                              37/105 (35.2)\
                                                                                                                                                                                                          0/15 (0.0)                                                                                                                                                                                    1/16 (6.3)

  Moleda et al. 2013 \[[@B25-jcm-08-01431]\]             Universal one-step screening                   Local (Polish) \*\*        WHO                         OGTT                                       13/199 (6.5)\                                                                                                WHO                            OGTT                                              73/199 (36.7)\
                                                                                                                                                                                                          0/50 (0.0)                                                                                                                                                                                    6/50 (12.0)

  Huopio et al. 2014 \[[@B17-jcm-08-01431]\]             Universal one-step screening                   Local (Finnish) \*\*\*     ADA                         OGTT                                       28/489 (5.7)\                                                                                                ADA                            OGTT                                              233/489 (47.6)\
                                                                                                                                                                                                          1/385 (0.3)                                                                                                                                                                                   100/385 (26.0)

  Kramer et al. 2014 \[[@B57-jcm-08-01431]\]             Universal two-step screening                   NDDG                       CDA                         OGTT                                       7/105 (6.7)\                                                                                                 CDA                            OGTT                                              31/105 (29.5)\
                                                                                                                                                                                                          2/232 (0.9)                                                                                                                                                                                   29/232 (12.5)

  Mai et al. 2014 \[[@B44-jcm-08-01431]\]                NR                                             ADA                        ADA                         OGTT                                       19/190 (10.0)\                                                                                               \-                             \-                                                \-
                                                                                                                                                                                                          0/80 (0.0)                                                                                                                                                                                    

  Ajala et al. 2015 \[[@B26-jcm-08-01431]\]              Universal two-step screening                   CDA                        NR                          OGTT or FPG                                8/90 (8.9)\                                                                                                  NR                             OGTT or FPG                                       41/90 (45.6)\
                                                                                                                                                                                                          1/59 (1.7)                                                                                                                                                                                    10/59 (16.9)

  Cormier et al. 2015 \[[@B27-jcm-08-01431]\]            NR                                             NR                         CDA                         OGTT                                       40/214 (18.7)\                                                                                               CDA                            OGTT                                              121/214 (56.5)\
                                                                                                                                                                                                          1/82 (1.2)                                                                                                                                                                                    11/82 (13.4)

  Kaul et al. 2015 \[[@B45-jcm-08-01431]\]               Universal two-step screening                   CDA                        NR                          NR                                         1881/8731 (13.5)\                                                                                            \-                             \-                                                \-
                                                                                                                                                                                                          3195/231,352 (1.4)                                                                                                                                                                            

  Lekva et al. 2015 \[[@B28-jcm-08-01431]\]              Universal one-step screening                   IADPSG                     ADA                         OGTT                                       1/52 (1.9)\                                                                                                  ADA                            OGTT                                              8/52 (15.4)\
                                                                                                                                                                                                          0/248 (0.0)                                                                                                                                                                                   10/248 (4.2)

  Pintaudi et al. 2015 \[[@B46-jcm-08-01431]\]           Selective screening based on risk factors      ADA                        NR                          NR                                         773/3851 (20.1)\                                                                                             \-                             \-                                                \-
                                                                                                                                                                                                          128/11,553 (1.1)                                                                                                                                                                              

  Sreelakshmi et al. 2015 \[[@B47-jcm-08-01431]\]        NR                                             NR                         NR                          NR                                         6/60 (10.0)\                                                                                                 \-                             \-                                                \-
                                                                                                                                                                                                          1/120 (0.8)                                                                                                                                                                                   

  Vigneault et al. 2015 \[[@B29-jcm-08-01431]\]          NR                                             NR                         CDA                         OGTT                                       40/216 (10.5)\                                                                                               CDA                            OGTT                                              122/216 (56.5)\
                                                                                                                                                                                                          1/83 (1.2)                                                                                                                                                                                    11/83 (13.3)

  Cho et al. 2016 \[[@B48-jcm-08-01431]\]                NR                                             NR                         NR                          NR                                         249/2962 (8.4)\                                                                                              \-                             \-                                                \-
                                                                                                                                                                                                          1642/50,147 (3.3)                                                                                                                                                                             

  Domínguez-Vigo et al. 2016 \[[@B49-jcm-08-01431]\]     Universal two-step screening                   NDDG, 1979                 ADA                         NR                                         41/308 (13.3)\                                                                                               \-                             \-                                                \-
                                                                                                                                                                                                          1/130 (0.8)                                                                                                                                                                                   

  Goueslard et al. 2016 \[[@B20-jcm-08-01431]\]          NR                                             NR                         NR                          NR                                         1266/62,958 (2.0)\                                                                                           \-                             \-                                                \-
                                                                                                                                                                                                          1674/1,452,429 (0.1)                                                                                                                                                                          

  Noctor et al. 2016 \[[@B30-jcm-08-01431]\]             Universal one-step screening                   IADPSG                     ADA                         OGTT                                       6/270 (2.2)\                                                                                                 ADA                            OGTT                                              64/270 (23.7)\
                                                                                                                                                                                                          0/388 (0.0)                                                                                                                                                                                   14/388 (3.6)

  Sina et al. 2016 \[[@B50-jcm-08-01431]\]               NR                                             NR                         WHO                         NR                                         21/53 (39.6)\                                                                                                \-                             \-                                                \-
                                                                                                                                                                                                          18/179 (10.1)                                                                                                                                                                                 

  Bond et al. 2017 \[[@B51-jcm-08-01431]\]               NR                                             CDA                        NR                          NR                                         6147/34,686 (17.7)\                                                                                          \-                             \-                                                \-
                                                                                                                                                                                                          472/34,686 (1.4)                                                                                                                                                                              

  Gadgil et al. 2017 \[[@B31-jcm-08-01431]\]             NR                                             NR                         NR                          OGTT                                       14/40 (35.0)\                                                                                                NR                             OGTT                                              11/40 (27.5)\
                                                                                                                                                                                                          73/374 (19.5)                                                                                                                                                                                 115/374 (30.7)

  Herath et al. 2017 \[[@B52-jcm-08-01431]\]             NR                                             WHO, 1999                  WHO                         OGTT or FPG                                73/119 (61.3)\                                                                                               \-                             \-                                                \-
                                                                                                                                                                                                          14/240 (5.8)                                                                                                                                                                                  

  Minooee et al. 2017 \[[@B32-jcm-08-01431]\]            Universal one-step screening                   WHO, 1999                  ADA                         OGTT                                       49/476 (10.3)\                                                                                               ADA                            OGTT                                              279/476 (58.6)\
                                                                                                                                                                                                          93/1982 (4.7)                                                                                                                                                                                 877/1982 (44.2)

  Retnakaran et al. 2017 \[[@B3-jcm-08-01431]\]          Universal two-step screening                   CDA                        NR                          NR                                         15,585/56,884 (24.4)\                                                                                        \-                             \-                                                \-
                                                                                                                                                                                                          49,397/1,458,195 (3.4)                                                                                                                                                                        

  Simmons et al. 2017 \[[@B33-jcm-08-01431]\]            Universal one-step screening                   ADIPS                      WHO                         OGTT                                       6/52 (11.5)\                                                                                                 WHO                            OGTT                                              4/52 (7.9)\
                                                                                                                                                                                                          100/2582 (3.9)                                                                                                                                                                                209/2582 (8.1)

  Tobias et al. 2017 \[[@B19-jcm-08-01431]\]             NR                                             NR                         NR                          NR                                         1008/5292 (19.0)\                                                                                            \-                             \-                                                \-
                                                                                                                                                                                                          4078/84,187 (4.8)                                                                                                                                                                             

  Daly et al. 2018 \[[@B18-jcm-08-01431]\]               NR                                             NR                         NR                          NR                                         895/9118 (9.8)\                                                                                              \-                             \-                                                \-
                                                                                                                                                                                                          142/37,281 (0.4)                                                                                                                                                                              

  Gunderson et al. 2018 \[[@B53-jcm-08-01431]\]          NR                                             NR                         ADA                         OGTT, FPG or HbA1c                         56/155 (36.1)\                                                                                               \-                             \-                                                \-
                                                                                                                                                                                                          126/1083 (11.6)                                                                                                                                                                               

  Huvinen et al. 2018 \[[@B34-jcm-08-01431]\]            Universal one-step screening                   CC                         NR                          OGTT                                       9/179 (5.0)\                                                                                                 NR                             OGTT                                              29/179 (16.2)\
                                                                                                                                                                                                          3/154 (1.9)                                                                                                                                                                                   11/154 (7.1)

  Lowe et al. 2018 \[[@B11-jcm-08-01431]\]               Universal one-step screening                   IADPSG                     ADA                         OGTT                                       71/663 (10.7)\                                                                                               ADA                            OGTT                                              200/508 (39.4)\
                                                                                                                                                                                                          63/3946 (1.6)                                                                                                                                                                                 728/3945 (18.5)

  McKenzie-Sampson et al. 2018 \[[@B56-jcm-08-01431]\]   Universal two-step screening                   NR                         \-                          \-                                         \-                                                                                                           \-                             \-                                                \-

  Shen et al. 2018 \[[@B35-jcm-08-01431]\]               Universal two-step screening                   WHO, 1999                  ADA                         OGTT                                       114/1263 (9.0)\                                                                                              ADA                            OGTT                                              401/1080 (34.0)\
                                                                                                                                                                                                          7/705 (1.0)                                                                                                                                                                                   198/698 (28.4)

  Sudasinghe et al. 2018 \[[@B36-jcm-08-01431]\]         NR                                             WHO, 1999                  WHO                         OGTT                                       11/59 (18.6)\                                                                                                WHO                            OGTT                                              17/59 (28.9)\
                                                                                                                                                                                                          3/57 (5.3)                                                                                                                                                                                    3/57 (5.3)

  **C.**                                                                                                                                                                                                                                                                                                                                                                                                

                                                         **GDM Stroke/Total**\                          **GDM MI/Total**\                                                                                                                                                                                                                                                                               
                                                         **NGT Stroke/Total (AR, %)**                   **NGT MI/Total (AR, %)**                                                                                                                                                                                                                                                                        

  Freibert et al. 2011 \[[@B54-jcm-08-01431]\]           \-\                                            5/146 (3.42)\                                                                                                                                                                                                                                                                                   
                                                         -                                              46/2558 (1.80)                                                                                                                                                                                                                                                                                  

  Goueslard et al. 2016 \[[@B20-jcm-08-01431]\]          71/62,958 (0.11)\                              26/62 958 (0.04)\                                                                                                                                                                                                                                                                               
                                                         1181/1,452,429 (0.08)                          257/1,452,429 (0.02)                                                                                                                                                                                                                                                                            

  Tobias et al. 2017 \[[@B19-jcm-08-01431]\]             33/5292 (0.62)\                                49/5292 (0.93)\                                                                                                                                                                                                                                                                                 
                                                         520/84,187 (0.62)                              563/84,187 (0.67)                                                                                                                                                                                                                                                                               

  Daly et al. 2017 \[[@B18-jcm-08-01431]\]               14/9118 (0.15)\                                14/9118 (0.15)\                                                                                                                                                                                                                                                                                 
                                                         50/37,281 (0.13)                               22/37,281 (0.06)                                                                                                                                                                                                                                                                                

  McKenzie-Sampson et al. 2018 \[[@B56-jcm-08-01431]\]   181/67,356 (0.27)\                             280/67 356 (0.42)\                                                                                                                                                                                                                                                                              
                                                         2207/1,003,311 (0.22)                          2219/1,003,311 (0.22)                                                                                                                                                                                                                                                                           
  ------------------------------------------------------ ---------------------------------------------- -------------------------- --------------------------- ------------------------------------------ ------------------------------------------------------------------------------------------------------------ ------------------------------ ------------------------------------------------- ----------------------------

GDM: gestational diabetes mellitus; MI: myocardial infarction; NGT: normal glucose tolerance; T2DM: type 2 diabetes mellitus; No matched controls: normal glucose tolerant women not matched by other characteristics to the GDM group; ADA: American Diabetes Association; ADIPS: Australasian Diabetes in Pregnancy Society; CC: Carpenter and Coustan; CDA: Canadian Diabetes Association; GDA; German Diabetes Association; IADPSG: International Association of Diabetes and Pregnancy Study Groups; NDDG: National Diabetes Data Group; WHO: World Health Organization; NR: not reported; OGTT: Oral Glucose Tolerance Test; BG: blood glucose; PG: plasma glucose; FPG: fasting plasma glucose; AR: absolute risk; SD: standard deviation; IQR: interquartile range. \* Local (Swedish): one abnormal value on a 2 h 75 g OGTT with the following values: 2 h BG ≥ 9.0 mmol/L (PG ≥ 10.0 mmol/L). \*\* Local (Polish): FPG ≥ 100 mg/dL and/or 2 h PG ≥ 140 mg/dL. \*\*\* Local (Finnish): one or more abnormal values on a 2 h 75 g OGTT with the following values: until September 2001---FPG \> 4.8 mmol/L, 1 h BG \> 10.0 mmol/L, and 2 h BG \> 8.7 mmol/L; since September 2001---FPG \> 4.8 mmol/L, 1 h PG \> 11.2 mmol/L, and 2 h PG \> 9.9 mmol/L.
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###### 

Subgroup analyses for T2DM and prediabetes: (**A**) subgroup analyses for T2DM and (**B**) subgroup analyses for prediabetes.

  ------------------------------------- ----------------------- ---------------------------- ---------------------------- ------------------ -------------- --------------- ---------------------------
  **A.**                                                                                                                                                                    
  **Subgroup**                          **Number of studies**   **Weight of subjects (%)**   **Relative risk (95% CI)**   ***p* for RR**     **I^2^ (%)**   **τ** **^2^**   ***p* for heterogeneity**
  **Diagnostic criteria GDM**                                                                                             **0.17** \*                                       
  IADPSG                                5                       7.6                          6.45 (4.74, 8.77)            \<0.00001          0              0.00            0.57
  Other criteria                        23                      53.4                         9.08 (6.96, 11.85)           \<0.00001          98             0.21            \<0.00001
  NR                                    12                      39.0                         6.04 (3.61, 10.10)           \<0.00001          99             0.68            \<0.00001
  **Screening strategy GDM**                                                                                              **0.09** \*                                       
  Universal two-step                    8                       19.7                         11.56 (7.50, 17.84)          \<0.00001          99             0.21            0.0007
  Universal one-step                    11                      18.0                         4.66 (2.68, 8.10)            \<0.00001          67             0.36            \<0.00001
  Selective                             3                       8.1                          8.17 (2.45, 27.23)           0.0006             90             0.82            \<0.0001
  NR                                    18                      54.2                         7.44 (4.96, 11.15)           \<0.00001          99             0.58            \<0.00001
  **Follow-up, yr**                                                                                                       **\<0.00001** \*                                  
  \<3                                   7                       9.5                          13.15 (5.60, 30.85)          \<0.00001          51             0.54            0.05
  3--\<6                                12                      25.2                         15.95 (14.53, 17.52)         \<0.00001          38             0.00            0.09
  6--\<10                               7                       17.6                         6.23 (2.54, 15.26)           \<0.0001           99             1.07            \<0.00001
  10--\<15                              9                       29.5                         6.82 (5.33, 8.71)            \<0.00001          96             0.09            \<0.00001
  ≥20                                   3                       11.8                         3.75 (3.14, 4.48)            \<0.00001          42             0.01            0.18
  NR                                    2                       6.4                          2.10 (1.32, 3.32)            0.002              17             0.02            0.27
  **Age during pregnancy, yr**                                                                                            **\<0.00001** \*                                  
  \<30                                  2                       7.8                          3.93 (3.69, 4.19)            \<0.00001          0              0.00            0.99
  30--\<35                              9                       9.1                          11.50 (7.39, 17.90)          \<0.00001          0              0.00            0.97
  ≥35                                   0                       \-                           \-                           \-                 \-             \-              \-
  NR                                    29                      83.1                         7.43 (5.92, 9.32)            \<0.00001          99             0.25            \<0.00001
  **Age postpartum, yr**                                                                                                  **\<0.00001** \*                                  
  \<30                                  1                       4.4                          5.06 (4.54, 5.64)            \<0.00001          NA             NA              NA
  30--\<35                              7                       14.4                         12.98 (7.89, 21.35)          \<0.00001          60             0.19            0.02
  ≥35                                   5                       13.4                         3.69 (1.76, 7.77)            0.0006             88             0.49            \<0.00001
  NR                                    27                      67.8                         7.87 (6.07, 10.21)           \<0.00001          99             0.27            \<0.00001
  **BMI in pregnancy, kg/m^2^**                                                                                           **\<0.00001** \*                                  
  \<25                                  1                       4.4                          3.93 (3.69, 4.19)            \<0.00001          NA             NA              NA
  25--\<30                              3                       5.3                          6.97 (5.05, 9.63)            \<0.00001          0              0.00            0.40
  ≥30                                   2                       1.0                          18.20 (2.46, 134.42)         0.004              0              0.00            0.98
  NR                                    34                      89.3                         7.51 (6.03, 9.36)            \<0.00001          99             0.25            \<0.00001
  **BMI follow-up, kg/m^2^**                                                                                              **\<0.00001** \*                                  
  \<25                                  5                       9.0                          15.64 (14.68, 16.66)         \<0.00001          0              0.00            0.69
  25--\<30                              11                      21.6                         4.21 (2.84, 6.25)            \<0.00001          76             0.18            \<0.00001
  ≥30                                   2                       6.6                          5.03 (4.52, 5.61)            \<0.00001          0              0.00            0.38
  NR                                    22                      62.8                         8.63 (6.65, 11.22)           \<0.00001          99             0.25            \<0.00001
  **Ethnicity**                                                                                                           **0.02** \*                                       
  Caucasian                             10                      10.5                         7.59 (4.06, 14.20)           \<0.00001          23             0.22            0.23
  Asian                                 4                       9.8                          4.87 (1.44, 16.41)           0.01               89             1.22            \<0.00001
  Pacific Islander                      2                       6.2                          3.59 (2.29, 5.62)            \<0.00001          0              0.00            0.56
  Middle Eastern                        1                       2.2                          3.20 (1.15, 8.92)            0.03               NA             NA              NA
  Mixed                                 7                       18.5                         10.76 (5.55, 20.85)          \<0.00001          98             0.53            \<0.00001
  NR                                    16                      52.8                         8.09 (6.06, 10.80)           \<0.00001          99             0.26            \<0.00001
  **Diagnostic criteria T2DM**                                                                                            **0.28** \*                                       
  WHO                                   7                       16.9                         5.27 (3.62, 7.66)            \<0.00001          54             0.10            0.04
  ADA                                   13                      24.9                         7.94 (4.22, 14.94)           \<0.00001          88             0.79            \<0.00001
  CDA                                   3                       3.2                          11.31 (4.01, 31.91)          \<0.00001          0              0.00            0.78
  GDA                                   1                       0.5                          2.64 (0.16, 43.56)           0.50               \-             \-              \-
  NR                                    16                      54.5                         8.40 (6.29, 11.22)           \<0.00001          99             0.27            \<0.00001
  **Screening method T2DM**                                                                                               **0.23** \*                                       
  OGTT                                  19                      30.6                         5.42 (3.43, 8.55)            \<0.00001          71             0.47            \<0.00001
  FGP                                   1                       0.5                          17.78 (1.10, 288.10)         0.04               NA             NA              NA
  HbA1c                                 0                       \-                           \-                           \-                 \-             \-              \-
  Multiple methods                      6                       16.8                         7.23 (3.78, 13.84)           \<0.00001          93             0.45            \<0.00001
  NR                                    14                      52.1                         9.38 (6.99, 12.58)           \<0.00001          99             0.27            \<0.00001
  **B.**                                                                                                                                                                    
  **Subgroup**                          **Number of studies**   **Weight of subjects (%)**   **Relative risk (95% CI)**   ***p* for RR**     **I^2^ (%)**   **τ** **^2^**   ***p* for heterogeneity**
  **Diagnostic criteria GDM**                                                                                             **0.73** \*                                       
  IADPSG                                5                       22.7                         2.79 (1.30, 5.96)            0.008              84             0.52            \<0.00001
  Other criteria                        12                      59.5                         2.03 (1.57, 2.62)            \<0.00001          82             0.10            \<0.00001
  NR                                    4                       17.7                         2.24 (0.86, 5.80)            0.10               83             0.72            0.0004
  **Screening strategy GDM**                                                                                              **0.63** \*                                       
  Universal two-step                    5                       23.6                         3.22 (1.46, 7.10)            0.004              89             0.57            \<0.00001
  Universal one-step                    10                      53.0                         2.18 (1.60, 2.97)            \<0.00001          89             0.15            \<0.00001
  Selective                             1                       1.4                          5.64 (0.83, 38.28)           0.08               NA             NA              NA
  NR                                    5                       22.0                         2.63 (1.24, 5.57)            0.01               79             0.52            0.0007
  **Follow-up, yr**                                                                                                       **0.04** \*                                       
  \<3                                   6                       26.5                         4.16 (2.46, 7.03)            \<0.00001          66             0.25            0.01
  3--\<6                                7                       29.8                         3.10 (1.40, 6.87)            0.005              90             0.84            \<0.00001
  6--\<10                               4                       21.8                         2.00 (1.55, 2.58)            \<0.00001          15             0.01            0.32
  10--\<15                              2                       16.9                         1.68 (1.05, 2.68)            0.03               97             0.11            \<0.00001
  ≥20                                   0                       \-                           \-                           \-                 \-             \-              \-
  NR                                    2                       5.0                          0.31 (0.02, 5.36)            0.42               86             3.66            0.008
  **Age during pregnancy, yr**                                                                                            **0.66** \*                                       
  \<30                                  0                       \-                           \-                           \-                 \-             \-              \-
  30--\<35                              6                       32.1                         2.66 (1.68, 4.21)            \<0.0001           77             0.21            0.0005
  ≥35                                   0                       \-                           \-                           \-                 \-             \-              \-
  NR                                    15                      67.9                         2.36 (1.76, 3.16)            \<0.00001          89             0.18            \<0.00001
  **Age postpartum, yr**                                                                                                  **0.20** \*                                       
  \<30                                  1                       0.7                          27.17 (1.70, 434.17)         0.02               NA             NA              NA
  30--\<35                              4                       18.4                         3.26 (0.94, 11.37)           0.06               91             1.40            \<0.00001
  ≥35                                   5                       29.8                         1.93 (1.26, 2.96)            0.002              93             0.16            \<0.00001
  NR                                    11                      51.2                         2.73 (1.91, 3.88)            \<0.00001          71             0.20            0.0002
  **BMI in pregnancy, kg/m^2^**                                                                                           **0.0003** \*                                     
  \<25                                  0                       \-                           \-                           \-                 \-             \-              \-
  25--\<30                              3                       17.3                         1.98 (1.61, 2.42)            \<0.00001          52             0.01            0.12
  ≥30                                   1                       5.9                          6.57 (3.76, 11.47)           \<0.00001          NA             NA              NA
  NR                                    17                      76.8                         2.46 (1.82, 3.33)            \<0.00001          86             0.23            \<0.00001
  **BMI follow-up, kg/m^2^**                                                                                              **0.14** \*                                       
  \<25                                  2                       9.1                          0.95 (0.31, 2.96)            0.93               27             0.38            0.24
  25--\<30                              11                      58.1                         2.61 (1.88, 3.63)            \<0.00001          91             0.19            \<0.00001
  ≥30                                   1                       3.4                          1.25 (0.45, 3.48)            0.67               NA             NA              NA
  NR                                    7                       29.4                         3.06 (1.97, 4.77)            \<0.00001          52             0.17            0.05
  **Ethnicity**                                                                                                           **\<0.00001** \*                                  
  Caucasian                             10                      44.1                         4.04 (2.43, 6.72)            \<0.00001          83             0.45            \<0.00001
  Asian                                 2                       4.2                          0.71 (0.01, 68.22)           0.88               94             10.20           \<0.0001
  Pacific Islander                      1                       3.7                          0.95 (0.37, 2.46)            0.92               NA             NA              NA
  Middle Eastern                        1                       3.4                          1.25 (0.45, 3.48)            0.67               NA             NA              NA
  Mixed                                 3                       21.1                         2.16 (1.92, 2.44)            \<0.00001          0              0.00            0.80
  NR                                    4                       23.5                         1.32 (1.12, 1.56)            0.001              53             0.01            0.09
  **Diagnostic criteria prediabetes**                                                                                     **0.33** \*                                       
  WHO                                   5                       17.9                         2.76 (1.42, 5.36)            0.003              58             0.30            0.05
  ADA                                   9                       50.1                         2.19 (1.60, 2.98)            \<0.00001          92             0.14            \<0.00001
  CDA                                   3                       18.4                         3.39 (2.22, 5.17)            \<0.00001          49             0.07            0.14
  GDA                                   0                       \-                           \-                           \-                 \-             \-              \-
  NR                                    4                       13.5                         1.55 (0.48, 5.04)            0.46               81             1.02            0.001
  **Screening method prediabetes**                                                                                        **0.63** \*                                       
  OGTT                                  20                      94.4                         2.44 (1.90, 3.13)            \<0.00001          88             0.18            \<0.00001
  FGP                                   0                       \-                           \-                           \-                 \-             \-              \-
  HbA1c                                 0                       \-                           \-                           \-                 \-             \-              \-
  Multiple methods                      1                       5.6                          2.69 (1.46, 4.94)            0.001              NA             NA              NA
  NR                                    0                       \-                           \-                           \-                 \-             \-              \-
  ------------------------------------- ----------------------- ---------------------------- ---------------------------- ------------------ -------------- --------------- ---------------------------

BMI: body mass index (kg/m^2^); NR: not reported; RR: relative risk; 95% CI: confidence interval; NA: not applicable; WHO: World Health Organization; ADA: American Diabetes Association; CDA: Canadian Diabetes Association; GDA: German Diabetes Association. \* *p* values for test for subgroup differences. I^2^ represents the total between-studies variability, τ^2^ represents the between-studies variance between studies, and *p* for heterogeneity represents the *p* values for the heterogeneity within subgroups.

[^1]: Shared first co-authorship.
